- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03362073
Perfusion intraveineuse continue de kétamine chez des patients cancéreux en phase terminale (CIVIK)
Une étude de phase II sur l'efficacité et l'innocuité de la perfusion intraveineuse continue de kétamine chez des patients cancéreux en phase terminale souffrant de douleur cancéreuse réfractaire
To establish the role of ketamine in hospitalized terminally ill cancer patients with refractory cancer pain, using continuous intravenous infusion of ketamine
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- There are approximately 20 percent patients of refractory cancer pain, which is troubled with uncontrolled pain though treatment including opioids.
- Ketamine has been showed the performance of Ketamine, N-methyl-D-aspartate (NMDA) receptor blocker, in refractory cancer pain based on prior studies.
- We cannot yet confirm the role of Ketamine comparing the benefit and risk due to incompatible results of prior studies. Additionally, most of prior studies were studied in heterogenous groups, which are from beginning of palliative chemotherapy to terminal status, so role of ketamine was not assessed in homogeneous terminally ill cancer patients. And they has used mostly 'bolus intravenous infusion' or 'continuous subcutaneous infusion (CSCI)', relatively rare in continuous intravenous infusion (CIVI).
- The bolus intravenous method is convenient but is concerned with leading to relatively severe adverse events due to poor general condition of terminally ill cancer patients, the CSCI method is not recommended because of adverse events (AEs) such as skin irritation. On the contrary, the CIVI method using gradual increasing ketamine minimizes AEs and is free of skin irritation. Most of hospitalized terminally ill cancer patients has proper IV access using intravascular devices (chemoport or PICC). So, CIVI method is suitable to hospitalized terminally ill cancer patients.
- This study assess the efficacy and safety of 5-days CIVI gradual dose titration of Ketamine in terminally ill cancer patients with refractory cancer pain.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Corée du Sud, 50612
- Pusan National University Yangsan Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Among patients with histologically or cytologically confirmed malignancy, patients with expected survival time of several months or less due to a progressive disease without additional anticancer treatment.
- Patients with refractory cancer pain, which cases of requesting 4 or more breakthrough analgesics or increase of baseline analgesics (average pain score ≥ 4 or Personalized pain goal) in spite of 120 mg/day or more of intravenous Morphine Equivalent Daily Dose
- Hospitalized patients with intravascular access during at least 5 days
- Age 18 or older
- Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
-
Patients who were treated with ketamine for pain control within 6 months
-
Patients who have been treated with radiotherapy within 4 weeks or plan to intervention for pain control during study period
-
Cancer pain cannot be excluded the Opioid induced hyperalgesia
-
Concomitant severe medical, surgical, or disease or problems which were contraindicated to application of Ketamine or have possibilities of unexpected medical problems caused be the Ketamine
- confirmed or assumed central nervous system lesion which lead to increased intracranial pressure
- Arrhythmia (supra-ventricular tachycardia, ventricular arrhythmia (frequent premature ventricular contraction, bigeminy, Ventricular tachycardia)
- history of hemorrhagic stroke or seizure within 3 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ketamine
continuous intravenous infusion of ketamine |
Application of ketamine using continuous intravenous infusion method during 5 days
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall response rate
Délai: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
complete pain response plus partial pain response
|
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change of pain intensity
Délai: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Delineate changes of pain intensity daily, from the time baseline until 5th days after application of ketamine. Pain intensity is defined as the mean of terdiurnal checked patient reported pain score during a day. |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Rescue analgesics for breakthrough pain
Délai: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Dose and number of rescue analgesics for breakthrough pain |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Patient's satisfaction about Ketamine by a newly developed question in this study
Délai: at the 5th days or drop-out, assess up to 2 years
|
Satisfaction about pain control and Ketamine-related distress during application of ketamine was evaluated by questions as follows: "How do you feel satisfaction about ketamine?" (at 5th days or drop-out) |
at the 5th days or drop-out, assess up to 2 years
|
|
Guardian's satisfaction about Ketamine by a newly developed question in this study
Délai: at the 5th days or drop-out, assess up to 2 years
|
Satisfaction about pain control and Ketamine-related distress during application of ketamine was evaluated by questions as follows: "How do you feel satisfaction about ketamine?" (at 5th days or drop-out) |
at the 5th days or drop-out, assess up to 2 years
|
|
Rate of Ketamine-related adverse events
Délai: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Rate of Ketamine-related adverse events |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Rate of early discontinuation
Délai: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Rate of discontinuation due to Ketamine related AEs |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Overall survival
Délai: From date of enrollment until death or discharge/transfer, assess up to 2 years
|
Time from application of ketamine until death or discharge/transfer |
From date of enrollment until death or discharge/transfer, assess up to 2 years
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Kwonoh Park, MD, PhD, Pusan National University Yangsan Hospital
Publications et liens utiles
Publications générales
- van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 Sep;18(9):1437-49. doi: 10.1093/annonc/mdm056. Epub 2007 Mar 12.
- Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995 Oct;63(1):65-76. doi: 10.1016/0304-3959(95)00017-M.
- Hanks GW, Justins DM. Cancer pain: management. Lancet. 1992 Apr 25;339(8800):1031-6. doi: 10.1016/0140-6736(92)90546-f. No abstract available.
- Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt O, Rowett D, Currow DC. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012 Oct 10;30(29):3611-7. doi: 10.1200/JCO.2012.42.1081. Epub 2012 Sep 10.
- Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 2001 Oct;22(4):834-42. doi: 10.1016/s0885-3924(01)00340-2.
- Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000 Oct;20(4):246-52. doi: 10.1016/s0885-3924(00)00194-9.
- Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD003351. doi: 10.1002/14651858.CD003351.pub3.
- Park K, Kim JJ, Oh SB, Oh SY, Hong YJ, Kim SJ, Park EJ, Choi N, Shin SH, Kim S, Ko H. A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial). Am J Hosp Palliat Care. 2025 Mar;42(3):244-252. doi: 10.1177/10499091241252977. Epub 2024 May 16.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CIVIK
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .